Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 5/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840395 | 0.89 | CFTR (0.46) | CFTRBRAFEGLN1PIK3CAPIK3CD | |
| SCHEMBL23337488 | 0.89 | CFTR (0.46) | CFTRBRAFEGLN1PIK3CAPIK3CD | |
| SCHEMBL23336692 | 0.85 | BRAF (0.46) | CFTRBRAFWNT3APIK3CADGAT1 | |
| Hydrochloric Acid SCHEMBL23303955 | 0.84 | BRAF (0.45) | CFTRBRAFWNT3APIK3CADGAT1 | |
| SCHEMBL23303785 | 0.84 | BTK (0.50) | CFTRBRAFEGLN1 | |
| SCHEMBL23303990 | 0.80 | MEN1 (0.41) | CFTRWNT3A | |
| SCHEMBL23303716 | 0.76 | BTK (0.47) | — | |
| SCHEMBL27167883 | 0.74 | MEN1 (0.36) | CFTRWNT3A | |
| SCHEMBL25238414 | 0.73 | PIK3CB (0.40) | BRAFEGLN1PIK3CAPIK3CDPIK3CG | |
| SCHEMBL4658348 | 0.69 | BRAF (0.77) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | CFTR 4425/4885BRAF 118/4885EGLN1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.